RESUMEN
Concomitant heart and peripheral blood determinations were performed on 40 fatal cases involving nordiazepam (20 cases) and bromazepam (20 cases). The heart blood concentration for the two drugs (588 ng/mL for nordiazepam and 802 ng/mL for bromazepam) does not differ from the corresponding peripheral blood concentration (587 ng/mL for nordiazepam and 883 ng/mL for bromazepam). The mean ratios for the heart and peripheral blood concentrations were 0.95 for nordiazepam and 0.86 for bromazepam. No postmortem redistribution was observed for these two benzodiazepines. The authors thus suggest that corresponding heart blood can be proposed in the quantitative analysis of these drugs when peripheral blood is unavailable. The present study also shows the stability of the two drugs after a year of storage.
Asunto(s)
Ansiolíticos/análisis , Ansiolíticos/sangre , Bromazepam/análisis , Bromazepam/sangre , Miocardio/química , Nordazepam/análisis , Nordazepam/sangre , Adulto , Ansiolíticos/farmacocinética , Biotransformación , Bromazepam/análogos & derivados , Bromazepam/farmacocinética , Cromatografía Líquida de Alta Presión , Femenino , Humanos , Masculino , Nordazepam/farmacocinética , Oxazepam/análisis , Oxazepam/sangre , Espectrofotometría UltravioletaRESUMEN
The number of reports on drug facilitated crimes is increasing these last years. Apart from ethanol and cannabis, benzodiazepines (BZD) and analogs are the most common drugs reported to be used probably due to their amnesic and sedative properties. We have developed a rapid and sensitive method using LC-MS/MS triple stage quadrupole (TSQ) for the determination of single exposure to bromazepam (Lexomil, 6 mg) and clonazepam (Rivotril, 2 mg) in urine and hair of healthy volunteers. Chromatography was carried out on a Uptisphere ODB 5 microm, 2.1 mm x 150 mm column (Interchim) with a gradient of acetonitrile and formate 2 mM buffer, pH 3. Urine was extracted with Toxitube A (Varian) and allowed the detection of bromazepam, 3-hydroxy-bromazepam, clonazepam and 7-Aminoclonazepam for more than 6 days. Head hair, collected 1 month after the exposure, was treated by incubation with Soerensen buffer pH 7.6, followed by liquid-liquid extraction with dichloromethane for common BZD. A specific pre-treatment for amino-BZD, with an incubation of 15 min at 95 degrees C in 0.1 N NaOH before liquid-liquid extraction with dichloromethane, gave better recoveries and repeatability. After single exposure, bromazepam was present in powdered hair at 28 pg/mg and 7-Aminoclonazepam at 22 pg/mg in the first 1-cm segment, while no clonazepam was detectable. This method was applied in two forensic cases. It allowed us to determine bromazepam in urine 3 days after the alleged offense and in cut head hair at a concentration of 6.7 pg/mg only in the 2-cm proximal segment. The other case showed the presence of clonazepam and 7-Aminoclonazepam in urine a few hours after the offense and the presence of 7-Aminoclonazepam at about 3.2 pg/mg in axillary hair 4 months later.
Asunto(s)
Bromazepam/análogos & derivados , Bromazepam/análisis , Clonazepam/análogos & derivados , Clonazepam/análisis , Crimen , Moduladores del GABA/análisis , Cabello/química , Detección de Abuso de Sustancias/métodos , Adulto , Cromatografía Liquida , Femenino , Medicina Legal/métodos , Humanos , Masculino , Espectrometría de Masa por Ionización de ElectrosprayRESUMEN
Among the different 1,4-benzodiazepine urinary metabolites, those of bromazepam possess distinctive chemical features that may be used in their selective isolation and detection. The detection of bromazepam metabolites in urine was carried out using EMIT d.a.u., thin-layer chromatography (TLC), and gas chromatography-mass spectrometry (GC-MS). The positive EMIT d.a.u. benzodiazepine assay for bromazepam was found to be due to the 3-hydroxybromazepam (3HOB) metabolite. The detection by TLC and GC-MS was carried out after enzyme or acid hydrolysis of the glucuronide conjugates. Both the 2-amino-3-hydroxy5-bromobenzoylpyridine (AHBBP) metabolite and the acid hydrolysis product of 3-HOB, 2-amino-5-bromobenzoylpyridine (ABBP), were selectively detected by TLC. The bromazepam metabolites in urine could be both isolated and detected selectively by GC-MS in the presence of the metabolites of other 1,4-benzodiazepines that were sometimes used in combination with bromazepam. Both 3-HOB and AHBBP were detected by GC-MS only after trimethylsilyl (TMS) derivatization and not as the free compounds or the acetyl derivatives. Only ABBP was detected in three forms: ABBP, the TMS derivative, and the acetyl derivative. Evidence has been obtained from the enzyme hydrolysis and the TLC studies for the formation of the glucuronide conjugate of AHBBP at the 3-OH group rather than at the 2-NH2 group. All the results have been validated using reference 3-HOB and AHBBP.
Asunto(s)
Bromazepam/análogos & derivados , Bromazepam/orina , Cromatografía en Capa Delgada , Técnica de Inmunoensayo de Enzimas Multiplicadas , Cromatografía de Gases y Espectrometría de Masas , Detección de Abuso de Sustancias/métodos , Bromazepam/análisis , Bromazepam/metabolismo , HumanosRESUMEN
A gaschromatographic assay method is described for the determination of Ro 5-3350 (bromazepam) using Ro 5-4547 (methylbromazepam) as internal standard. After alkaline ether extraction the bromazepam and methylbromazepam obtained from sulfuric acid reextraction are hydrolyzed to ABBP and to MABBP, respectively. After neutralization, the bromo-pyridine-benzophenones are extracted with ether and dissolved in hexane after evaporation of the ether. Under the described gaschromatographic conditions it was found that MABBP and ABBP have retention times of 10.5 and 12.5 min, respectively. The limit of sensitivity is situated at 5 ng/ml of plasma. The specificity is satisfactory since the metabolite which might have interfered (hydroxy-3-bromazepam) appears only at very low concentrations in the blood. The linearity of the calibration curve was confirmed for plasma concentrations up to 100 ng/ml.
Asunto(s)
Ansiolíticos/sangre , Bromazepam/sangre , Benzofenonas/sangre , Biotransformación , Bromazepam/análogos & derivados , Cromatografía de Gases , Humanos , Hidrólisis , Piridinas/sangreRESUMEN
A high-performance liquid chromatographic method for the determination of bromazepam in plasma and of its main metabolites in urine is described. The unchanged drug is extracted from plasma with dichloromethane, using Extrelut 1 extraction tubes. The residue from this extract is subsequently analysed by reversed-phase high-performance liquid chromatography with ultraviolet detection (230 nm). The limit of detection is 6 ng/ml of plasma, using a 1-ml specimen. For the determination of the metabolites, the urine samples are incubated to effect enzymatic deconjugation and are then extracted with dichloromethane. Following two clean-up steps (back extractions), the final residue is analysed on the same reversed-phase system as the plasma samples. The limit of detection for the two metabolites is 200 ng/ml.
Asunto(s)
Ansiolíticos/metabolismo , Bromazepam/metabolismo , Animales , Bromazepam/análogos & derivados , Bromazepam/orina , Bovinos , Cromatografía Líquida de Alta Presión/métodos , Glucuronidasa/metabolismo , Semivida , Humanos , Hidroxilación , Hígado/enzimología , Piridinas/orina , Espectrofotometría UltravioletaRESUMEN
Six healthy volunteers were given a standard regimen of bromazepam (Lexotan) (6 mg t.d.s.) for five days. Compliance with the study protocol was demonstrated by measuring drug concentrations at steady state. Steady-state levels of 3-hydroxybromazepam were also determined. These were found to be much lower than the concentrations of bromazepam. Since the metabolite is known to be less active than the parent drug, it is likely that the metabolic will contribute little to the pharmacological effects of the drug in humans. Antipyrine pharmacokinetics were studied immediately before bromazepam administration was started, after the dosing schedule had been completed and one week after dosing had been discontinued. There were no significant changes in the disposition of antipyrine on any occasion. Therefore, although previous studies have demonstrated enzyme induction in laboratory animals given high doses of bromazepam, similar effects are unlikely to occur in humans being treated with therapeutic doses of the compound.